GlassScriptPhysician profile
Taryn A Hope
NPI 1457587933
$3,025.57
in general payments reported to CMS, 2019-2025
27 companies · $685 in 2025
The $685 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $309 · 2022: $424 · 2023: $702 · 2024: $906 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,292.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.53 | 2021-2025 | |
| Amgen INC. | $581.33 | 2021-2025 | Enbrel, Tavneos, Otezla |
| Astrazeneca Pharmaceuticals LP | $208.07 | 2021-2025 | Saphnelo |
| Bioventus LLC | $161.08 | 2022-2025 | Durolane, Durolane, Xcell |
| Fresenius Kabi USA, LLC | $160.58 | 2023-2025 | Idacio |
| Novartis Pharmaceuticals Corporation | $140.93 | 2023-2025 | |
| Lilly USA, LLC | $126.95 | 2021-2024 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $118.76 | 2022-2025 | Benlysta |
| Aurinia Pharma U.S., INC. | $100.73 | 2021-2025 | Lupkynis |
| Janssen Biotech, INC. | $100.00 | 2021-2025 | Tremfya |
| Pfizer INC. | $70.51 | 2022-2025 | |
| Genentech USA, INC. | $65.70 | 2021-2025 | Gazyva, Rituxan, Actemra |
| Horizon Therapeutics Plc | $60.28 | 2022-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $59.32 | 2023 | Acthar |
| Ucb, INC. | $52.09 | 2023-2024 | Bimzelx, Cimzia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $51.59 | 2022-2025 | Renflexis, Hadlima |
| Ani Pharmaceuticals, INC. | $49.94 | 2023-2025 | Purified Cortrophin Gel |
| Pacira Pharmaceuticals Incorporated | $49.34 | 2023 | Iovera, Zilretta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.44 | 2023-2024 | |
| Genzyme Corporation | $29.61 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $22.99 | 2025 | |
| Sobi, INC | $21.72 | 2024 | |
| Pacira Therapeutics, INC. | $20.62 | 2021 | |
| Sandoz INC. | $19.37 | 2024 | Hyrimoz |
| Kyowa Kirin, INC. | $19.08 | 2024 | Crysvita |
| Merck Sharp & Dohme LLC | $17.78 | 2021 | |
| Depuy Synthes Sales INC. | $15.23 | 2023 | Monovisc, Orthovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taryn Hope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.